Dexamethasone Intensol and Glecaprevir and pibrentasvir
Determining the interaction of Dexamethasone Intensol and Glecaprevir and pibrentasvir and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Dexamethasone may reduce the blood levels of glecaprevir in some patients, which may make the medication less effective in treating hepatitis C infection. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inducers of P-glycoprotein (P-gp) or CYP450 3A4 may decrease the plasma concentrations of glecaprevir and pibrentasvir. Both antiviral agents are substrates of the P-gp efflux transporter, and glecaprevir is additionally a substrate of the CYP450 3A4 isoenzyme. When a single 300 mg-120 mg dose of glecaprevir-pibrentasvir was administered to 12 study subjects following multiple dosing of the potent inducer rifampin at 600 mg once daily, glecaprevir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 86% and 88%, respectively, while pibrentasvir Cmax and AUC decreased by 83% and 87%, respectively. Likewise, when a single dose of glecaprevir-pibrentasvir was administered to 10 study subjects following multiple dosing of carbamazepine 200 mg twice daily, glecaprevir Cmax and AUC decreased by approximately two-thirds, while pibrentasvir Cmax and AUC decreased by approximately one-half.
MANAGEMENT: The potential for diminished pharmacologic effects of glecaprevir and pibrentasvir should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.
Generic Name: dexamethasone
Brand name: Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak, De-Sone LA, Dexacen-4, Dexasone, Dexasone LA, Solurex, Solurex LA, Decadron, DexPak, TaperDex, Zema-Pak, ZoDex, Zonacort
Synonyms: n.a.
Generic Name: glecaprevir / pibrentasvir
Brand name: Mavyret
Synonyms: Glecaprevir and Pibrentasvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexamethasone Intensol-Gleevec
- Dexamethasone Intensol-Glenmax PEB DM
- Dexamethasone Intensol-Glenmax PEB DM FORTE
- Dexamethasone Intensol-Gleolan
- Dexamethasone Intensol-Gleostine
- Dexamethasone Intensol-Gliadel
- Glecaprevir and pibrentasvir-Dexamethasone intraocular
- Glecaprevir and pibrentasvir-Dexamethasone ophthalmic
- Glecaprevir and pibrentasvir-Dexamethasone Oral Drops
- Glecaprevir and pibrentasvir-Dexamethasone SodiumPhosphate
- Glecaprevir and pibrentasvir-Dexamethasone Solution (Drops)
- Glecaprevir and pibrentasvir-Dexamethasone Tablets